Company intelligence / Profile preview
Stem Cell Therapeutics Corp.
- Ownership
- Private
- Development stage
- Other
Overview
Completed Phase I clinical trial of hCG entitled "Open labeled, uncontrolled pharmacokinetic study of single intramuscular hCG dose in healthy male volunteers" which demonstrated hCG can cross the blood brain barrier. Entered Phase II clinical trials for treatment of stroke using a combination of erythropoietin and hCG[1].
- Therapeutic areas
- Neurology
- Modalities
- Drug-based stem cell stimulation therapy
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Stem Cell Therapeutics Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stem Cell Therapeutics Corp..